Celularity (CELU) Stock Forecast, Price Target & Predictions
CELU Stock Forecast
Celularity stock forecast is as follows: an average price target of $6.00 (represents a 287.10% upside from CELU’s last price of $1.55) and a rating consensus of 'Hold', based on 2 wall street analysts offering a 1-year stock forecast.
CELU Price Target
The average price target for Celularity (CELU) is $6.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 287.10% upside from CELU's last price of $1.55.
CELU Analyst Ratings
According to 2 Wall Street analysts, Celularity's rating consensus is 'Hold'. The analyst rating breakdown for CELU stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 2 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Celularity Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 23, 2022 | Asthika Goonewardene | Truist Financial | $6.00 | $2.79 | 115.05% | 287.10% |
The latest Celularity stock forecast, released on Aug 23, 2022 by Asthika Goonewardene from Truist Financial, set a price target of $6.00, which represents a 115.05% increase from the stock price at the time of the forecast ($2.79), and a 287.10% increase from CELU last price ($1.55).
Celularity Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.55 | $1.55 | $1.55 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Celularity stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Celularity's last price of $1.55. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 12, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Apr 26, 2022 | Truist Financial | - | Hold | Downgrade |
Celularity's last stock rating was published by Morgan Stanley on Sep 12, 2022. The company gave CELU a "Equal-Weight" rating, the same as its previous rate.
Celularity Financial Forecast
Celularity Revenue Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $3.94M | $4.13M | - | - | $5.93M | $4.86M | - |
| Avg Forecast | $5.20M | $5.30M | $4.80M | $4.40M | $4.71M | $27.22M | $26.80M | $6.90M | $5.49M | $5.74M | $5.44M | $5.09M | $4.58M | $1.73M |
| High Forecast | $5.20M | $5.30M | $4.80M | $4.40M | $4.71M | $27.22M | $26.80M | $6.90M | $5.49M | $5.74M | $5.44M | $5.09M | $4.58M | $1.73M |
| Low Forecast | $5.20M | $5.30M | $4.80M | $4.40M | $4.71M | $27.22M | $26.80M | $6.90M | $5.49M | $5.74M | $5.44M | $5.09M | $4.58M | $1.73M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | 0.57% | 0.75% | - | - | 1.17% | 1.06% | - |
Celularity's average Quarter revenue forecast for Jul 23 based on 1 analysts is $26.80M, with a low forecast of $26.80M, and a high forecast of $26.80M. CELU's average Quarter revenue forecast represents a 581.02% increase compared to the company's last Quarter revenue of $3.94M (Mar 23).
Celularity EBITDA Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | $-52.41M | $-32.84M | - | - | $-34.80M | $-655.00K | - |
| Avg Forecast | $-4.24M | $-4.32M | $-3.92M | $-3.59M | $-3.84M | $-22.21M | $-21.87M | $-5.63M | $-4.48M | $-4.68M | $-4.44M | $-50.45M | $-3.74M | $-1.41M |
| High Forecast | $-4.24M | $-4.32M | $-3.92M | $-3.59M | $-3.84M | $-22.21M | $-21.87M | $-5.63M | $-4.48M | $-4.68M | $-4.44M | $-40.36M | $-3.74M | $-1.41M |
| Low Forecast | $-4.24M | $-4.32M | $-3.92M | $-3.59M | $-3.84M | $-22.21M | $-21.87M | $-5.63M | $-4.48M | $-4.68M | $-4.44M | $-60.54M | $-3.74M | $-1.41M |
| Surprise % | - | - | - | - | - | - | - | 9.31% | 7.33% | - | - | 0.69% | 0.18% | - |
undefined analysts predict CELU's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Celularity's previous annual EBITDA (undefined) of $NaN.
Celularity Net Income Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | $-64.44M | $24.43M | - | - | $-88.97M | $-4.04M | - |
| Avg Forecast | $-32.16M | $-30.02M | $-30.02M | $-30.02M | $44.78M | $-6.43M | $-6.43M | $-51.46M | $-54.46M | $-56.10B | $-56.01B | $-52.35M | $-66.60B | $-73.97B |
| High Forecast | $-32.16M | $-30.02M | $-30.02M | $-30.02M | $44.78M | $-6.43M | $-6.43M | $-51.46M | $-54.46M | $-56.10B | $-56.01B | $-41.88M | $-66.60B | $-73.97B |
| Low Forecast | $-32.16M | $-30.02M | $-30.02M | $-30.02M | $44.78M | $-6.43M | $-6.43M | $-51.46M | $-54.46M | $-56.10B | $-56.01B | $-62.82M | $-66.60B | $-73.97B |
| Surprise % | - | - | - | - | - | - | - | 1.25% | -0.45% | - | - | 1.70% | 0.00% | - |
Celularity's average Quarter net income forecast for Mar 23 is $-51.46M, with a range of $-51.46M to $-51.46M. CELU's average Quarter net income forecast represents a -310.60% decrease compared to the company's last Quarter net income of $24.43M (Dec 22).
Celularity SG&A Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | $13.93M | $19.08M | - | - | $16.46M | $13.21M | - |
| Avg Forecast | $11.97M | $12.20M | $11.05M | $10.13M | $10.84M | $62.68M | $61.70M | $15.89M | $12.63M | $13.22M | $12.52M | $11.72M | $10.55M | $3.98M |
| High Forecast | $11.97M | $12.20M | $11.05M | $10.13M | $10.84M | $62.68M | $61.70M | $15.89M | $12.63M | $13.22M | $12.52M | $11.72M | $10.55M | $3.98M |
| Low Forecast | $11.97M | $12.20M | $11.05M | $10.13M | $10.84M | $62.68M | $61.70M | $15.89M | $12.63M | $13.22M | $12.52M | $11.72M | $10.55M | $3.98M |
| Surprise % | - | - | - | - | - | - | - | 0.88% | 1.51% | - | - | 1.40% | 1.25% | - |
Celularity's average Quarter SG&A projection for Jul 23 is $61.70M, based on 1 Wall Street analysts, with a range of $61.70M to $61.70M. The forecast indicates a 342.81% rise compared to CELU last annual SG&A of $13.93M (Mar 23).
Celularity EPS Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | $-0.41 | $0.31 | - | - | $-0.68 | $-0.03 | - |
| Avg Forecast | $-1.50 | $-1.40 | $-1.40 | $-1.40 | $2.09 | $-0.30 | $-0.30 | $-2.40 | $-2.54 | $-2.62 | $-2.61 | $-2.27 | $-3.11 | $-3.45 |
| High Forecast | $-1.50 | $-1.40 | $-1.40 | $-1.40 | $2.09 | $-0.30 | $-0.30 | $-2.40 | $-2.54 | $-2.62 | $-2.61 | $-2.27 | $-3.11 | $-3.45 |
| Low Forecast | $-1.50 | $-1.40 | $-1.40 | $-1.40 | $2.09 | $-0.30 | $-0.30 | $-2.40 | $-2.54 | $-2.62 | $-2.61 | $-2.27 | $-3.11 | $-3.45 |
| Surprise % | - | - | - | - | - | - | - | 0.17% | -0.12% | - | - | 0.30% | 0.01% | - |
According to 1 Wall Street analysts, Celularity's projected average Quarter EPS for Mar 23 is $-2.40, with a low estimate of $-2.40 and a high estimate of $-2.40. This represents a -874.19% decrease compared to CELU previous annual EPS of $0.31 (Dec 22).
Celularity Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.63 | $70.00 | 11011.11% | Buy |
| CNSP | CNS Pharmaceuticals | $0.11 | $0.50 | 354.55% | - |
| IMMX | Immix Biopharma | $1.58 | $7.00 | 343.04% | Buy |
| CELU | Celularity | $1.55 | $6.00 | 287.10% | Hold |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| EFTR | eFFECTOR Therapeutics | - | $5.50 | - | Buy |
CELU Forecast FAQ
Is Celularity a good buy?
No, according to 2 Wall Street analysts, Celularity (CELU) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of CELU's total ratings.
What is CELU's price target?
Celularity (CELU) average price target is $6 with a range of $6 to $6, implying a 287.10% from its last price of $1.55. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Celularity stock go up soon?
According to Wall Street analysts' prediction for CELU stock, the company can go up by 287.10% (from the last price of $1.55 to the average price target of $6), up by 287.10% based on the highest stock price target, and up by 287.10% based on the lowest stock price target.
Can Celularity stock reach $2?
CELU's average twelve months analyst stock price target of $6 supports the claim that Celularity can reach $2 in the near future.
What are Celularity's analysts' financial forecasts?
Celularity's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $65.63M (high $65.63M, low $65.63M), average EBITDA is $-53.548M (high $-53.548M, low $-53.548M), average net income is $-19.545M (high $-19.545M, low $-19.545M), average SG&A $151.11M (high $151.11M, low $151.11M), and average EPS is $-0.912 (high $-0.912, low $-0.912). CELU's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $19.7M (high $19.7M, low $19.7M), average EBITDA is $-16.074M (high $-16.074M, low $-16.074M), average net income is $-122M (high $-122M, low $-122M), average SG&A $45.36M (high $45.36M, low $45.36M), and average EPS is $-5.7 (high $-5.7, low $-5.7).
Did the CELU's actual financial results beat the analysts' financial forecasts?
Based on Celularity's last annual report (Dec 2022), the company's revenue was $17.98M, which missed the average analysts forecast of $21.76M by -17.38%. Apple's EBITDA was $-141M, beating the average prediction of $-64.05M by 120.35%. The company's net income was $14.19M, missing the average estimation of $-112B by -100.01%. Apple's SG&A was $66.02M, beating the average forecast of $50.09M by 31.80%. Lastly, the company's EPS was $0.0001, missing the average prediction of $-10.036 by -100.00%. In terms of the last quarterly report (Mar 2023), Celularity's revenue was $3.94M, missing the average analysts' forecast of $6.9M by -42.97%. The company's EBITDA was $-52.411M, beating the average prediction of $-5.63M by 830.95%. Celularity's net income was $-64.441M, beating the average estimation of $-51.458M by 25.23%. The company's SG&A was $13.93M, missing the average forecast of $15.89M by -12.29%. Lastly, the company's EPS was $-0.41, missing the average prediction of $-2.4 by -82.92%